Merck KGaA (OTCMKTS:MKKGY) Sees Large Volume Increase – Time to Buy?

Shares of Merck KGaA (OTCMKTS:MKKGYGet Free Report) saw an uptick in trading volume on Monday . Approximately 164,620 shares were traded during trading, an increase of 71% from the previous session’s volume of 96,264 shares.The stock last traded at $31.5910 and had previously closed at $31.58.

Wall Street Analysts Forecast Growth

MKKGY has been the subject of a number of research reports. HSBC upgraded Merck KGaA to a “hold” rating in a report on Monday, July 6th. Jefferies Financial Group started coverage on Merck KGaA in a research note on Tuesday, May 26th. They issued a “hold” rating for the company. Finally, Zacks Research upgraded shares of Merck KGaA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Merck KGaA has a consensus rating of “Hold”.

Get Our Latest Stock Analysis on MKKGY

Merck KGaA Trading Up 0.4%

The company has a debt-to-equity ratio of 0.36, a current ratio of 1.51 and a quick ratio of 1.00. The firm’s 50 day moving average is $32.17 and its 200 day moving average is $29.31. The company has a market capitalization of $20.47 billion, a PE ratio of 16.33, a P/E/G ratio of 2.61 and a beta of 0.98.

About Merck KGaA

(Get Free Report)

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.

Featured Articles

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.